Computationally Guided Design of BCR-ABL Tyrosine Kinase Inhibitors
Duan, C.; Chu, S. K. S.; Siegel, J. B.; Fell, J. S.
Show abstract
BCR-ABL tyrosine kinase inhibitors (TKI) are used to treat the chronic myeloid leukemia (CML). Many TKI have been developed as the primary treatment to the CML. Imatinib, a first generation TKI, directly targets BCR-ABL with effective results. As the disease becomes more advanced, patients start to develop resistance to imatinib. Due to this effect it is necessary to generate novel treatments for advanced stage CML. Computational tools can predict new drug candidates to target BCR-ABL. We have designed two new drug candidates with different levels of modification, based on the predicted structure activity relationships with BCR-ABL. These new drug candidates are predicted to have better binding affinities with BCR-ABL than imatinib, which can be more potent treatments of the disease.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 94%
- Development of a Novel Bruton's Tyrosine Kinase Inhibitor that exerts Anti-Cancer Activities Potentiates Response of Chemotherapeutic Agents In Multiple Myeloma Stem Cell-Like Cells 93%
- The mitochondrial deubiquitinase USP30 regulates AKT/mTOR signaling 92%
Similar papers in this journal
- Utilizing Heteroatom Types and Numbers from Extensive Ligand Libraries to Develop Novel hERG Blocker QSAR Models Using Machine Learning-based Classifiers 96%
- Support Vector Machine based prediction models for drug repurposing and designing novel drugs for colorectal cancer 94%
- Discovery of a Novel Non-Narcotic Analgesic Derived from the CL-20 Explosive: Synthesis, Pharmacology and Target Identification of Thio-wurtzine, a Potent Inhibitor of the Opioid Receptors and the Voltage-Dependent Calcium Channels 94%
Similar papers in this journal
- De novo drug designing coupled with brute force screening and structure guided lead optimization gives highly specific inhibitor of METTL3: a potential cure for Acute Myeloid Leukaemia 96%
- Pharmacophore modeling, 2D-QSAR, Molecular Docking and ADME studies for the discovery of inhibitors of PBP2a in MRSA 94%
- Structural analysis and ensemble docking revealed the binding modes of selected progesterone receptor modulators 94%
Similar papers in this journal
- Discovery of Z1362873773: A Novel Fascin Inhibitor from a Large Chemical Library for Colorectal Cancer 96%
- Mechanistic insights into the Japanese Encephalitis Virus RNA dependent RNA polymerase protein inhibition by bioflavonoids from Azadirachta indica 95%
- The Hidden Potential of PDE4 Inhibitor Rolipram: A Multifaceted Examination of its Inhibition of MMP2/9 Reveals Therapeutic Implications 93%
Similar papers in this journal
- Deep learning based predictive modeling to screen natural compounds against TNF-alpha for the potential management of Rheumatoid Arthritis: Virtual screening to comprehensive in silico investigation 96%
- Molecular docking, simulation and binding free energy analysis of small molecules as PfHT1 inhibitors 95%
- Structure-Guided Discovery and Characterization of Novel FLT3 Inhibitors for Acute Myeloid Leukemia Treatment 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.